(CercleFinance.com) – AstraZeneca announces that positive results from a phase III trial showed that Imfinzi (durvalumab) combined with TACE (a chemoembolization that blocks the hepatic artery to treat liver cancer liver) and bevacizumab demonstrated a ‘statistically and clinically significant’ improvement in progression-free survival (PFS) compared to TACE alone in patients with hepatocellular carcinoma (HCC).
“The addition of durvalumab and bevacizumab to TACE reduced the risk of disease progression or death by 23% in liver cancer patients eligible for embolization,” says Bruno Sangro, director of Liver Unit and Professor of Medicine at Clínica Universidad de Navarra, Pamplona (Spain) and Principal Investigator of the trial.
The findings will be presented today at the 2024 American Society of Clinical Oncology (ASCO GI) Gastrointestinal Cancers Symposium in San Francisco.
The trial will continue as planned to evaluate the key secondary endpoint of overall survival (OS).
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
